Bonova 150 mg (Tablet)
1 tablet kit: ৳ 2,507.52
Medicine Details
| Category | Details |
|---|---|
| Generic | Ibandronic acid |
| Company | Radiant pharmaceuticals ltd |
Indications
- Treatment of osteoporosis in women (specially postmenopausal)
- Prevention of osteoporosis in women (specially postmenopausal)
- Prevention and treatment of osteoporosis in men
Pharmacology
- Inhibition of bone resorption
- Prevents experimentally induced bone destruction
- Highly potent inhibitor of osteoclastic activity
- Reduces bone resorption
Dosage & Administration
- Recommended dose: one 150 mg film-coated tablet once a month
- Tablet should be taken on the same date each month
- Swallowed whole with a full glass of plain water
- Patients should not lie down for 60 minutes after taking the tablet
Interaction
- Likely interference with calcium supplements and antacids
- No interaction potential with tamoxifen or hormone replacement therapy
- No dosage adjustment required when co-administered with H2-antagonists
Contraindications
- Known hypersensitivity to ibandronic acid
- Uncorrected hypocalcemia
- Abnormalities of the esophagus delaying esophageal emptying
- Inability to stand or sit upright for at least 60 minutes
Side Effects
- Dyspepsia
- Nausea
- Diarrhea
- Abdominal pain
- Muscle aches
- Headaches
- Dizziness
Pregnancy & Lactation
- Not to be used during pregnancy
- No clinical experience in pregnant women
- Not to be used during lactation
Precautions & Warnings
- Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting therapy
- Caution in patients with active upper gastrointestinal problems
- Physicians should be alert to any signs or symptoms signaling a possible esophageal reaction
- Caution during concomitant medication with NSAIDs
- Risk of osteonecrosis of the jaw
Use in Special Populations
- No dosage adjustment for mild or moderate renal impairment
- No dosage adjustment for hepatic impairment
- No dosage adjustment for elderly patients
- Safety and efficacy not established in patients less than 18 years old
Overdose Effects
- Oral overdosage may result in upper gastrointestinal adverse events
- Milk or antacids should be given to bind the medication
- Vomiting should not be induced and the patient should remain fully upright
Therapeutic Class
Bisphosphonate preparations
Storage Conditions
Should be kept below 30°C temperature, away from light & moisture, and out of the reach of children